Moderna, Inc. (MRNA): Depreciation & Amortization
$211.00M
Year ended 2025-12-31
$229.00M
Trailing 12 months to 2026-06-30
-15.4%
3-year compound annual growth
+46.8%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $211.00M | +14.1% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $185.00M | -70.0% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $617.00M | +77.3% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $348.00M | +50.0% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $232.00M | +648.4% | 2023-02-24, From 2021-01-01 |
| 2020-12-31 | $31.00M | 0.0% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $31.00M | +24.7% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $24.86M | +21.1% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $20.54M | +35.9% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $15.11M | n/a | 2019-03-13, From 2016-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $211.00M | +14.1% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $193.75M | -4.7% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $29.05M | +0.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $11.39M | +11.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $97.36M | -11.4% |
| Novavax Inc (NVAX) | 2025-12-31 | $27.61M | -43.1% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.39M | +11.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $78.75M | +13.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $8.10M | +0.6% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗